We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$176M
Cap. Flow
-$78M
Cap. Flow %
-2.8%
Top 10 Hldgs %
39.13%
Holding
109
New
17
Increased
24
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$94.3M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$60.3M
3
AERI
Aerie Pharmaceuticals
AERI
+$54.9M
4
XENT
Intersect ENT, Inc
XENT
+$29.7M
5
CHRS icon
Coherus Oncology
CHRS
+$29.1M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$90.8M
2
CNC icon
Centene
CNC
+$19.7M
3
AXGN icon
Axogen
AXGN
+$18.7M
4
GKOS icon
Glaukos
GKOS
+$17.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 67.69%
2 Financials 0.96%
3 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$27.3M 0.98%
264,600
+12,400
+5% +$965K
XERS icon
27
Xeris Biopharma Holdings
XERS
$1.51B
$27.2M 0.98%
2,379,901
+24,765
+1% +$260K
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$27M 0.97%
1,217,668
+567,668
+87% +$13.3M
EHTH icon
29
eHealth
EHTH
$45.7M
$26.8M 0.96%
310,900
-128,709
-29% -$8.66M
DBVT
30
DBV Technologies
DBVT
$839M
$26.3M 0.95%
320,122
+150,000
+88% +$13.4M
DFBHU
31
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
$25.9M 0.93%
2,500,000
– –
STAA icon
32
STAAR Surgical
STAA
$1.21B
$25.8M 0.93%
+876,512
New +$25.3M
NVRO
33
DELISTED
NEVRO CORP.
NVRO
$25M 0.9%
386,000
-193,463
-33% -$12M
SILK
34
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$24.2M 0.87%
+499,030
New +$21.2M
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.35B
$23.9M 0.86%
6,292,980
-244,586
-4% -$1.47M
NVTA
36
DELISTED
Invitae Corporation
NVTA
$23.4M 0.84%
995,312
+582,112
+141% +$12.4M
MOH icon
37
Molina Healthcare
MOH
$11.9B
$21.5M 0.77%
150,000
+64,000
+74% +$8.77M
PTCT icon
38
PTC Therapeutics
PTCT
$6.42B
$21.2M 0.76%
471,000
+234,000
+99% +$9.24M
ARVN icon
39
Arvinas
ARVN
$517M
$20.3M 0.73%
921,234
– –
ADUS icon
40
Addus HomeCare
ADUS
$2.16B
$19M 0.68%
252,915
– –
BOLD
41
DELISTED
Audentes Therapeutics, Inc
BOLD
$18.7M 0.67%
493,901
– –
RETA
42
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$18.6M 0.67%
197,000
-167,000
-46% -$14.4M
SWAV
43
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$17.8M 0.64%
312,146
– –
HUM icon
44
Humana
HUM
$48B
$17.8M 0.64%
+67,000
New +$17M
KNSA icon
45
Kiniksa Pharmaceuticals
KNSA
$4.85B
$17.7M 0.64%
1,310,259
– –
AXGN icon
46
Axogen
AXGN
$2.11B
$17.6M 0.63%
891,306
-875,700
-50% -$18.7M
WVE icon
47
Wave Life Sciences
WVE
$1.11B
$17.5M 0.63%
669,260
+274,523
+70% +$7.7M
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$380M
$17.1M 0.61%
1,137,142
+857,142
+306% +$15M
CNC icon
49
Centene
CNC
$32.8B
$15.9M 0.57%
303,000
-364,000
-55% -$19.7M
ELV icon
50
Elevance Health
ELV
$83.1B
$15M 0.54%
53,000
– –
1
2
3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2019 Portfolio in Review

As of Q2 2019, Deerfield Management held 109 positions worth $2.78B, up 6.8% from $2.61B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Deerfield Management's Q2 2019 filing shows 17 new, 24 increased, 19 reduced and 12 closed positions. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Deerfield Management's largest Q2 2019 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M.
  • Deerfield Management added most to Viatris in Q2 2019, an estimated $94.3M increase.
  • Deerfield Management's biggest Q2 2019 reduction was Centene, cutting an estimated $19.7M.
  • Deerfield Management fully exited Portola Pharmaceuticals, Inc. in Q2 2019, selling an estimated $90.8M.
  • Deerfield Management's ten largest holdings make up 39% of its $2.78B portfolio in Q2 2019.
  • Deerfield Management opened 17 new positions and closed 12 in Q2 2019.
  • Deerfield Management's portfolio value rose 6.8% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.